Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).

Eisai

Status: Completed

Conditions: Dementia With Lewy Body Disease

Treatments: Drug: Donepezil Hydrochloride

Study type: Observational

Funder types: Industry

Identifiers

NCT02448784

ART09T

Details and patient eligibility

About

To investigate long term safety (especially about Parkinsonism) and efficacy of donepezil hydrochloride in clinical practice as well as its proper use information in participants with DLB.

Enrollment: 591 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Naive participants diagnosed as DLB

Exclusion criteria

1. Participants with a history of donepezil hydrochloride product administration in the past
2. Participants who have already been registered in this surveillance
3. Participants with a history of hypersensitivity to any ingredients of donepezil hydrochloride or piperidine derivatives

Trial design

591 participants in 1 patient group

Participants with DLB

Description:

Participants with DLB who will receive donepezil hydrochloride per approved label.

Treatment:

Drug: Donepezil Hydrochloride